Nathan Fitzsimmons serves as the Chief Science Officer at Dyve Biosciences, a clinical-stage life sciences company. In this role, he contributes to the development of highly efficacious topical therapies designed to offer excellent tolerability and minimal side effects, aiming to improve the patient treatment journey.

Prior to his current position, Fitzsimmons was a management consultant with McKinsey & Company.